Biogen says oral MS drug study meets target: "Biogen Idec Inc. said Monday that patients taking a multiple sclerosis drug it is developing showed significant reductions in brain lesions compared with those on a placebo. The mid-stage study included about 250 patients across 10 European countries. The drug, BG-12, is being developed by Biogen and Switzerland's Fumapharm AG for patients with relapsing-remitting multiple sclerosis. The companies said the therapy significantly reduced patients' brain lesions after six months as viewed using an MRI scan...."